ArticleTropical medicine and health2020
Multidrug-resistant and extended-spectrum beta-lactamase-producing uropathogens in children in Bhaktapur, Nepal.
Article in Tropical medicine and health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Prevalence and Antibiotic Resistance Pattern ofInfection and drug resistance · 2026Article
- Current Trends in Antibiotic Resistance Patterns of Pathogens in Urinary Tract Infections in Children in Karaganda, Kazakhstan.Iranian journal of medical sciences · 2025Article
- Trends in Antibiotic Resistance ofPathogens (Basel, Switzerland) · 2025Article
- Uropathogens and Their Antimicrobial Resistance Profile at a Pediatric Tertiary Care Hospital in Kathmandu, Nepal.The American journal of tropical medicine and hygiene · 2025Article
- Incidence of Extended Spectrum β-Lactamase Genes (ESBLs) among community and health care infection in Mansoura University Hospital, Egypt.BMC microbiology · 2025Article
- Phenotypic characterization of ESBL-producing urinary isolates of E. coli and Klebsiella spp. in a tertiary care children's hospital in Nepal.Tropical medicine and health · 2024Article
- Article
- In Vitro Activity of Omadacycline and Comparator Antibiotics against Extended-Spectrum Beta-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Systematic Review and Meta-analysis on Extended-Spectrum β-lactamases ProducingMicrobiology insights · 2023Review
- Antibiotics Prescription, Dispensing Practices and Antibiotic Resistance Pattern in Common Pathogens in Nepal: A Narrative Review.Microbiology insights · 2023Review
- TEM,CTX-M,SHV Genes in ESBL-ProducingAntibiotics (Basel, Switzerland) · 2022Article
- Prevalence of Multidrug-ResistantJournal of tropical medicine · 2022Review
- Antibiotic resistance patterns of urinary tract pathogens in children from Central Romania.Experimental and therapeutic medicine · 2021Article
- Detection ofDiseases (Basel, Switzerland) · 2021Article
- Antibiotic resistance patterns in uropathogens: insights from a Nepalese tertiary care setting.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe emergence of multidrug-resistant (MDR) and extended-spectrum beta-lactamase (ESBL)-producing uropathogens has complicated the treatment of urinary tract infections (UTI). Paediatric UTI is a common illness, which if not treated properly, may lead to acute and long-term complications, such as renal abscess, septicaemia, and renal scarring. This study aimed to determine the prevalence of MDR and ESBL-producing uropathogens among children.
methodsDuring the study period (April 2017-April 2018), midstream urine samples were collected following aseptic procedures from children < 16 years in Siddhi Memorial Hospital. Standard culture and biochemical tests were performed to identify uropathogens and antimicrobial susceptibility test was done by modified Kirby-Bauer disc diffusion method following Clinical and Laboratory Standard Institute (CLSI) guidelines. ESBL-producing uropathogens were screened by ceftazidime (30 μg) and cefotaxime (30 μg) discs, and confirmed by the combination disc tests: ceftazidime + clavulanic acid (30/10 μg) or cefotaxime + clavulanic acid (30/10 μg) as recommended by CLSI.
resultsWe processed 5545 non-repeated urine samples from the children with symptoms of UTI. A significant growth of uropathogens was observed in 203 samples (3.7%). The median age of the children was 24 months (interquartile range (IQR), 12-53 months).
conclusionsNitrofurantoin, ofloxacin, and amikacin can be used for the empirical treatment for UTI in children in Bhaktapur, Nepal. MDR and ESBL-producing uropathogens are prevalent; this warrants a continuous surveillance of antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.